Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. 2003 Sep 1 92(5):595-7.Īssociation of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. 2003 Jul 146(1):42-7.Īssociation of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. 2003 Jun 15(3):189-96.Īngiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial. 2002 Nov 144(5):790-5.ĭistance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. 2002 Jun 13(3):133-9.ĭeterminants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction insights from TIMI 14 and InTIME-II. The smoker’s paradox: insights from the angiographic substudies of the TIMI trials. 2001 Aug 15 88(4):353-8.Įarly coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). 2001 May 29 103(21):2550-4.Įarly noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. 2001 May 53(1):6-11.Ĭombination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. 2001 Feb 15 87(4):450-3, A6.Ībciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. 2000 Dec 21(23):1944-53.Ĭan we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. 2000 Aug 298(1-2):85-97.Ĭombination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy. 2000 Jun 13 101(23):2690-5.ĭegree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction trials). High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. 2000 Feb 1 85(3):299-304.īridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and “facilitated” PCI. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. 1999 Nov 1 34(5):1403-12.Ībciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. 1999 Oct 34(4):974-82.ĭeterminants of coronary blood flow after thrombolytic administration. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. TIMI 14 evaluated the benefit of abciximab bolus plus 12 hour infusion alone or in conjunction with reduced dose thrombolytic therapy among patients presenting with ST elevation myocardial infarction.Ībciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |